TrialPediatric cardiology2026

Phase 2 Open-label, Single-arm, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Camostat Mesylate in Patients with Protein-losing Enteropathy After Fontan Operation.

Woo Young Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.